- Previous Close
1.4700 - Open
1.4800 - Bid 1.4600 x 100
- Ask 1.5200 x 200
- Day's Range
1.4700 - 1.5500 - 52 Week Range
1.1900 - 17.8250 - Volume
548,837 - Avg. Volume
682,017 - Market Cap (intraday)
78.587M - Beta (5Y Monthly) 1.04
- PE Ratio (TTM)
-- - EPS (TTM)
-2.9700 - Earnings Date Nov 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.33
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
www.alxoncology.com89
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: ALXO
View More
Performance Overview: ALXO
Trailing total returns as of 2024-11-26, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALXO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALXO
View MoreValuation Measures
Market Cap
78.59M
Enterprise Value
-60.15M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.57
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-49.24%
Return on Equity (ttm)
-98.94%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-151.16M
Diluted EPS (ttm)
-2.9700
Balance Sheet and Cash Flow
Total Cash (mrq)
148.57M
Total Debt/Equity (mrq)
12.69%
Levered Free Cash Flow (ttm)
-74.55M